Ovarian reserve and oocyte maturity in women with malignancy undergoing in vitro maturation treatment

ArticleinFertility and sterility 95(5):1621-3 · April 2011with9 Reads
Impact Factor: 4.59 · DOI: 10.1016/j.fertnstert.2010.12.041 · Source: PubMed


    To evaluate ovarian reserve and oocyte maturity in women with malignancy.
    A case-control study.
    University teaching hospital.
    We evaluated all women with malignancy who underwent in vitro maturation treatment for fertility preservation from the year 2003 to 2009. The results were compared with those of an age-matched infertile control group.
    In vitro maturation treatment.
    Ovarian reserve and oocyte maturity.
    Women with malignancy of the breast (n = 87), hematologic malignancy (n = 16), gynecologic or abdominal malignancy (n = 9), and other malignancies (n = 16) were compared with infertile control women (n = 79). The age was similar in all groups except in women with hematologic malignancy where they were younger than the control group (24.9 ± 1.1 years vs. 30.8 ± 0.4 years, confidence interval 4.0-9.5). Baseline FSH in this group was also lower than in the control group. Women with breast cancer had a lower number of retrieved oocytes than the control group (95% confidence interval 0-5). There were no significant differences in antral follicle count, percentage of mature oocytes on collection day, and percentage of metaphase II oocytes matured in vitro among all groups of women.
    Women with breast cancer have fewer numbers of retrieved oocytes than infertile controls. Ovarian reserve and oocyte maturity in other types of malignancy are similar to those in the control group.